Treatment of Withdrawal Symptoms and Prevention of Relapse in Patients With Tramadol Abuse
Status:
Completed
Trial end date:
2022-06-15
Target enrollment:
Participant gender:
Summary
Tramadol abuse is a public health problem in Egypt. There are no approved medications for
treatment of withdrawal symptoms or prevention of relapse in patients with tramadol abuse.
The objective of this study was to compare the efficacy of venlafaxine and lofixidine in
treating the withdrawal symptoms and to compare between venlafaxine and naltrexone in relapse
prevention of tramadol abuse. Patients with tramadol abuse will be divided randomly to use
venlafaxine or lofixidine after discontinuation of tramadol. The efficacy will be measured by
the Clinical Opiate Withdrawal Scale. The medications will be used for 10 days after
discontinuation of tramadol. After the detoxification stage, patients who used venlafaxine
will continue to use it while patients who used lofixidine will use naltrexone during the
relapse prevention phase (2 months).